Swedish Orphan Biovitrum saw no growth in patent filings in April and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Swedish Orphan Biovitrum’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Swedish Orphan Biovitrum has been focused on protecting inventions in Australia(AU) with one publication in Q2 2024
The Australia(AU) Patent Office dominates the patent grants with nearly 33% of grants. The Australia(AU), Canada(CA), and Israel(IL) patent Office are among the top ten patent offices where Swedish Orphan Biovitrum is filings its patents. Among the top granted patent authorities, Swedish Orphan Biovitrum has 33% of its grants in Australia(AU), 33% in Canada(CA) and 33% in Israel(IL).
Immatics could be the strongest competitor for Swedish Orphan Biovitrum
Pain related patents lead Swedish Orphan Biovitrum portfolio
Swedish Orphan Biovitrum has highest number of patents in pain.
For comprehensive analysis of Swedish Orphan Biovitrum's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

